Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.44 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.44 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 4/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 4/20 | 0.42 |
| ▸ | DNM2 | P50570 | 2/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21512515 | 0.80 | EGFR (0.50) | EGFRMAPK1KDM4EALDH1A1 | |
| SCHEMBL29969091 | 0.80 | EGFR (0.50) | EGFRMAPK1KDM4EALDH1A1 | |
| SCHEMBL5495588 | 0.78 | FLT3 (0.47) | EGFRFLT3 | |
| SCHEMBL2621732 | 0.77 | EGFR (0.49) | EGFRFLT3MAPK1KDM4EALDH1A1 | |
| SCHEMBL12192994 | 0.73 | IKBKB (0.46) | DYRK1AGSK3BROCK1WNT1 | |
| SCHEMBL30834216 | 0.73 | CYP1A2 (0.53) | EGFRKDM4EALDH1A1 | |
| SCHEMBL27201452 | 0.73 | CYP1A2 (0.53) | EGFRKDM4EALDH1A1 | |
| SCHEMBL2671476 | 0.73 | CLK4 (0.56) | EGFRCLK4CDK5GSK3ACDK9 | |
| SCHEMBL26679803 | 0.72 | ABL1 (0.46) | CLK4CDK5GSK3ACDK9TAOK1 | |
| SCHEMBL1585465 | 0.72 | EGFR (0.43) | EGFRDNM2MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
| WO-2016014674-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | EGFR 2900/4885CLK4 3290/4885CDK5 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.